Art. -Nr.: HY-50514

AT9283

9 Cited Publications

Kundenbewertung

Based on 9 publication(s) in Google Scholar

AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC₅₀s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.67%
CAS. Nr.: 896466-04-9
Formel: C₁₉H₂₃N₇O₂
Molecular Weight:381.43

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

AT9283 Chemical Structure

CAS. Nr.: 896466-04-9

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (9)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]

Aurora A

3 nM (IC₅₀)

Aurora B

3 nM (IC₅₀)

JAK3

1.1 nM (IC₅₀)

JAK2

1.2 nM (IC₅₀)

ABL(T315I)

4 nM (IC₅₀)

Flt-3

Alle JAK Isoform-spezifische Produkte anzeigen :

Alle Aurora Kinase Isoform-spezifische Produkte anzeigen :

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen :

Abl
Bcr-Abl

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	7 nM Compound: 69; AT9283	Antitumor activity against human A2780 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis Antitumor activity against human A2780 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis	[PMID: 35749986]
A549	IC₅₀	0.512 μM Compound: AT-9283	Antitumor activity against human A549 cells after 72 hrs by MTT assay Antitumor activity against human A549 cells after 72 hrs by MTT assay	[PMID: 23664099]
A549	IC₅₀	7 nM Compound: 69; AT9283	Antitumor activity against human A549 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis Antitumor activity against human A549 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis	[PMID: 35749986]
BaF3	IC₅₀	11 nM Compound: AT9283	Antiproliferative activity against mouse BaF3 cells harbouring ABL-T315I mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring ABL-T315I mutant assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35551036]
BaF3	IC₅₀	13 nM Compound: AT9283	Antiproliferative activity against mouse BaF3 cells harbouring wild type ABL assessed as cell growth inhibition measured after 72 hrs by MTT assay Antiproliferative activity against mouse BaF3 cells harbouring wild type ABL assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 35551036]
BaF3	IC₅₀	16 nM Compound: 69; AT9283	Antiproliferative activity against mouse BaF3 cells harboring wild-type JAK2 assessed as inhibition of cell proliferation by alamar blue assay Antiproliferative activity against mouse BaF3 cells harboring wild-type JAK2 assessed as inhibition of cell proliferation by alamar blue assay	[PMID: 35749986]
HCT-116	IC₅₀	0.09 μM Compound: AT9283	Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay	[PMID: 33109396]
HCT-116	IC₅₀	12 nM Compound: 16, AT9283	Cytotoxicity against human HCT116 cells assessed as number of colonies after 10 to 14 days by colony forming assay Cytotoxicity against human HCT116 cells assessed as number of colonies after 10 to 14 days by colony forming assay	[PMID: 19143567]
HCT-116	IC₅₀	7 nM Compound: 69; AT9283	Antitumor activity against human HCT-116 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis Antitumor activity against human HCT-116 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis	[PMID: 35749986]
HEL	IC₅₀	0.65 μM Compound: AT; AT-9283	Cytotoxicity against HEL cells assessed as inhibition of cell growth incubated under normoxic condition in presence of 3-cyclopropyl-1-(3-{5-[(morpholin-4-yl)methyl]-1H-1,3-benzodiazol-2-yl}-1H-pyrazol-4-yl)urea Cytotoxicity against HEL cells assessed as inhibition of cell growth incubated under normoxic condition in presence of 3-cyclopropyl-1-(3-{5-[(morpholin-4-yl)methyl]-1H-1,3-benzodiazol-2-yl}-1H-pyrazol-4-yl)urea	[PMID: 36805946]
HEL	IC₅₀	0.65 μM Compound: AT; AT-9283	Cytotoxicity against HEL cells assessed as inhibition of cell growth incubated under normoxic condition in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide Cytotoxicity against HEL cells assessed as inhibition of cell growth incubated under normoxic condition in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide	[PMID: 36805946]
HEL	IC₅₀	1.04 μM Compound: AT; AT-9283	Cytotoxicity against HEL cells assessed as inhibition of cell growth Cytotoxicity against HEL cells assessed as inhibition of cell growth	[PMID: 36805946]
HEL	IC₅₀	1.34 μM Compound: AT; AT-9283	Cytotoxicity against HEL cells assessed as inhibition of cell growth incubated under hypoxic condition in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide Cytotoxicity against HEL cells assessed as inhibition of cell growth incubated under hypoxic condition in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide	[PMID: 36805946]
HEL	IC₅₀	1.41 μM Compound: AT; AT-9283	Cytotoxicity against HEL cells assessed as inhibition of cell growth incubated under dark condition in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide Cytotoxicity against HEL cells assessed as inhibition of cell growth incubated under dark condition in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide	[PMID: 36805946]
HEL	IC₅₀	16 nM Compound: 69; AT9283	Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell proliferation by alamar blue assay Antiproliferative activity against HEL cells harboring JAK2 V617F mutant assessed as inhibition of cell proliferation by alamar blue assay	[PMID: 35749986]
HEL	IC₅₀	2.18 μM Compound: AT; AT-9283	Cytotoxicity against HEL cells assessed as inhibition of cell growth irradiated with 450 nm light and incubated in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide Cytotoxicity against HEL cells assessed as inhibition of cell growth irradiated with 450 nm light and incubated in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide	[PMID: 36805946]
HT-29	IC₅₀	0.383 μM Compound: AT-9283	Antitumor activity against human HT-29 cells after 72 hrs by MTT assay Antitumor activity against human HT-29 cells after 72 hrs by MTT assay	[PMID: 23664099]
HT-29	IC₅₀	7 nM Compound: 69; AT9283	Antitumor activity against human HT-29 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis Antitumor activity against human HT-29 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis	[PMID: 35749986]
HUVEC	IC₅₀	1.76 μM Compound: AT; AT-9283	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide Cytotoxicity against HUVEC cells assessed as inhibition of cell growth incubated in presence of N-tert-butyl-3-[[5-methyl-2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]amino]benzenesulfonamide	[PMID: 36805946]
HUVEC	IC₅₀	1.77 μM Compound: AT; AT-9283	Cytotoxicity against HUVEC cells assessed as inhibition of cell growth Cytotoxicity against HUVEC cells assessed as inhibition of cell growth	[PMID: 36805946]
HUVEC	IC₅₀	1.793 μM Compound: AT9283	Cytotoxicity against HUVEC assessed as reduction in cell growth measured after 72 hrs by CCK8 assay Cytotoxicity against HUVEC assessed as reduction in cell growth measured after 72 hrs by CCK8 assay	[PMID: 33109396]
K562	IC₅₀	0.748 μM Compound: AT9283	Antiproliferative activity against human K562 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay Antiproliferative activity against human K562 cells assessed as reduction in cell growth measured after 72 hrs by CCK8 assay	[PMID: 33109396]
K562	IC₅₀	1.6 μM Compound: AT-9283	Antitumor activity against human K562 cells after 72 hrs by MTT assay Antitumor activity against human K562 cells after 72 hrs by MTT assay	[PMID: 23664099]
K562	IC₅₀	260 nM Compound: AT9283	Antiproliferative activity against human K562 cells harboring BCR-ABL assessed as inhibition of cell growth incubated for 4 hrs by CellTiter-Aqueous One assay Antiproliferative activity against human K562 cells harboring BCR-ABL assessed as inhibition of cell growth incubated for 4 hrs by CellTiter-Aqueous One assay	[PMID: 21964340]
LoVo	IC₅₀	0.553 μM Compound: AT-9283	Antitumor activity against human LoVo cells after 72 hrs by MTT assay Antitumor activity against human LoVo cells after 72 hrs by MTT assay	[PMID: 23664099]
MCF7	IC₅₀	7 nM Compound: 69; AT9283	Antitumor activity against human MCF7 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis Antitumor activity against human MCF7 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis	[PMID: 35749986]
MIA PaCa-2	IC₅₀	7 nM Compound: 69; AT9283	Antitumor activity against human MIA PaCa-2 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis Antitumor activity against human MIA PaCa-2 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis	[PMID: 35749986]
NOMO-1	IC₅₀	>10 μM Compound: AT9283	Antiproliferative activity against human NOMO-1 cells harboring MLL-AF9 assessed as inhibition of cell growth incubated for 4 hrs by CellTiter-Aqueous One assay Antiproliferative activity against human NOMO-1 cells harboring MLL-AF9 assessed as inhibition of cell growth incubated for 4 hrs by CellTiter-Aqueous One assay	[PMID: 21964340]
SET-2	IC₅₀	16 nM Compound: 69; AT9283	Antiproliferative activity against human SET2 cells harboring JAK2 V617F mutant assessed as inhibition of cell proliferation by alamar blue assay Antiproliferative activity against human SET2 cells harboring JAK2 V617F mutant assessed as inhibition of cell proliferation by alamar blue assay	[PMID: 35749986]
SW-620	IC₅₀	7 nM Compound: 69; AT9283	Antitumor activity against human SW620 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis Antitumor activity against human SW620 cells assessed as inhibition of colony formation incubated for 10 to 14 days by crystal violet staining based analysis	[PMID: 35749986]
TF-1	IC₅₀	16 nM Compound: 69; AT9283	Antiproliferative activity against human TF-1 cells harboring wild-type JAK2 assessed as inhibition of cell proliferation by alamar blue assay Antiproliferative activity against human TF-1 cells harboring wild-type JAK2 assessed as inhibition of cell proliferation by alamar blue assay	[PMID: 35749986]
U-937	IC₅₀	6.7 μM Compound: AT-9283	Antitumor activity against human U937 cells after 72 hrs by MTT assay Antitumor activity against human U937 cells after 72 hrs by MTT assay	[PMID: 23664099]
Vero	CC₅₀	>20 μM Compound: 45; AT9283	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 33539089]

In Vitro

AT9283 leads to a clear polyploid phenotype by inhibiting the activity of Aurora B kinase in HCT116 cells with IC₅₀ of 30 nM. Furthermore, AT9283 also produces the potent inhibition on HCT116 colony formation^[1].
AT9283 induces apoptosis in a dose and time dependent manner and inhibits cell proliferation with an IC₅₀ < 1 μM in B-NHL cell lines^[2].
AT9283 inhibits growth, induces dose dependent cytotoxicity, and inhibits STAT3 signaling pathway in MM cell lines. T9283 inhibits phospho Histone H3 and phospho Aurora A at Thr 288. AT9283 increases G2/M phase and induces apoptosis of MM cells in a time-dependent manner^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In HCT116 human colon carcinoma xenograft bearing mice, AT9283 treatment (15 mg/kg and 20 mg/kg) for 16 days results in a significant tumor growth inhibition of 67% and 76%, respectively. In addition, AT9283 also exhibits a significantly longer half-life in tumors (2.5 hours) compared with plasma (0.5 hour) and modest oral bioavailability in mice^[1].
AT9283 (15 mg/kg) and docetaxel (10 mg/kg) alone has modest anti-tumor activity. T9283 at 20 mg/kg and AT9283 (15 or 20 mg/kg) plus docetaxel (10 mg/kg) demonstrate a statistically significant tumor growth inhibition and enhance survival inmouse xenograft model of mantle cell lymphoma^[2].
AT9283 (45 mg/kg, i.p.) inhibits tumor growth in mice. Two cycles of AT9283 45 mg/kg 14 hours after drug administration confirm decreased expression of phospho-Histone H3 and Aurora B in treated animals^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 896466-04-9
Appearance Solid
Molecular Weight 381.43
Formel C₁₉H₂₃N₇O₂
Color White to off-white
SMILES

O=C(NC1CC1)NC2=CNN=C2C3=NC4=CC=C(C=C4N3)CN5CCOCC5
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (9)

All

Sort by:

Journal Impact Factor

Sci Transl Med

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. [Abstract]

2018 Jul 18;10(450):eaaq1093. PMID: 30021885
J Adv Res

Strain specificity of lactobacilli with promoted colonization by galactooligosaccharides administration in protecting intestinal barriers during Salmonella infection. [Abstract]

2024 Feb:56:1-14. PMID: 36894120
PLoS Pathog

Bile acids promote the caveolae-associated entry of swine acute diarrhea syndrome coronavirus in porcine intestinal enteroids. [Abstract]

2022 Jun 13;18(6):e1010620. PMID: 35696443
Cancers (Basel)

Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening. [Abstract]

2022 Mar 19;14(6):1575. PMID: 35326726
Front Oncol

GEFT Inhibits Autophagy and Apoptosis in Rhabdomyosarcoma via Activation of the Rac1/Cdc42-mTOR Signaling Pathway. [Abstract]

2021 Jun 18:11:656608. PMID: 34221974
PLoS One

A novel small molecule screening assay using normal human chondrocytes toward osteoarthritis drug discovery. [Abstract]

2024 Nov 1;19(11):e0308647. PMID: 39485774
University of Washington

2025.
bioRxiv

2025 February 21.
Patent

US20180263995A1.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (262.17 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.6217 mL

13.1086 mL

26.2171 mL

5 mM

0.5243 mL

2.6217 mL

5.2434 mL

10 mM

0.2622 mL

1.3109 mL

2.6217 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (6.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.55 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[2]

Lymphoma cells are seeded at 8,000 per well in 96-well culture plates and allowed to grow for 24 hr followed by the desired treatment with increasing concentrations of the indicated agents for 4 days. Viable cell densities are determined using a CellTiter 96 Cell Proliferation Assay. The IC₅₀ values are estimated by Calcusyn software.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

SCID mice are injected with 1×10⁷ Granta-519 MCL cells subcutaneously into the right hind flank. When tumors reached a volume of appr 60-100 mm³, mice are divided randomly (pair-matched) into six test groups with 12 mice per cohort: control group (saline), AT9283 (15 mg/kg IP Q1D, 5 days a week × 3 weeks) group, AT9283 (20 mg/kg IP Q1D, 5 days a week × 3 weeks) group, docetaxel (10 mg/kg IV Q1W × 3 weeks) group, AT9283 (15 mg/kg IP Q1D, 5 days a week × 3 weeks) + docetaxel (10 mg/kg IV Q1W × 3 weeks) group and AT9283 (20 mg/kg IP Q1D, 5 days a week × 3 weeks) + docetaxel (10 mg/kg IV Q1W × 3 weeks) group. The length (L) and width (W) of the subcutaneous tumors are measured by calipers and the tumor volume (TV) is calculated as: TV=(L × W²)/2. Mice are sacrificed at the end of study and overall survival for each cohort is analyzed by Kaplan–Meier method.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Howard S, et al. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity. Journal of Medicinal Chemistry (2009), 52(2), 379-388. [Content Brief]

[2]. Qi W, et al. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas. Int J Cancer. 2012 Jun 15;130(12):2997-3005. [Content Brief]

[3]. Santo L, et al. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15;17(10):3259-71 [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.6217 mL	13.1086 mL	26.2171 mL	65.5428 mL
	5 mM	0.5243 mL	2.6217 mL	5.2434 mL	13.1086 mL
	10 mM	0.2622 mL	1.3109 mL	2.6217 mL	6.5543 mL
	15 mM	0.1748 mL	0.8739 mL	1.7478 mL	4.3695 mL
	20 mM	0.1311 mL	0.6554 mL	1.3109 mL	3.2771 mL
	25 mM	0.1049 mL	0.5243 mL	1.0487 mL	2.6217 mL
	30 mM	0.0874 mL	0.4370 mL	0.8739 mL	2.1848 mL
	40 mM	0.0655 mL	0.3277 mL	0.6554 mL	1.6386 mL
	50 mM	0.0524 mL	0.2622 mL	0.5243 mL	1.3109 mL
	60 mM	0.0437 mL	0.2185 mL	0.4370 mL	1.0924 mL
	80 mM	0.0328 mL	0.1639 mL	0.3277 mL	0.8193 mL
	100 mM	0.0262 mL	0.1311 mL	0.2622 mL	0.6554 mL

Keywords

AT9283

9 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

AT9283

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

JAK/STAT Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Anti-COVID-19 Compound Library

Cytoskeleton Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Anti-Liver Cancer Compound Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) AT9283

Alle JAK Isoform-spezifische Produkte anzeigen

Alle Aurora Kinase Isoform-spezifische Produkte anzeigen

Alle Bcr-Abl Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (9)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

AT9283 Related Classifications

HY-50514 Related Classifications